211308-80-4

Basic information

• Product Name: 6-AMino-5-iodo-nicotinic acid Methyl ester
• Synonyms: 6-AMino-5-iodo-nicotinic acid Methyl ester;Methyl 6-aMino-5-iodonicotinate;Methyl 6-amino-5-iodopyridine-3-carboxylate;ethyl 6-amino-5-iodonicotinate;2-Amino-3-iodopyridine-5-carboxylic acid methyl ester
• CAS NO: 211308-80-4
• Molecular Formula: C₇H₇IN₂O₂
• Molecular Weight: 278.04715
• EINECS: -0
• Mol File: 211308-80-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 374.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.918±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.38±0.49(Predicted)
• CAS DataBase Reference: 6-AMino-5-iodo-nicotinic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 6-AMino-5-iodo-nicotinic acid Methyl ester(211308-80-4)
• EPA Substance Registry System: 6-AMino-5-iodo-nicotinic acid Methyl ester(211308-80-4)

Safety Data

• Hazardous Substances Data: 211308-80-4(Hazardous Substances Data)

Usage

General Description

6-Amino-5-iodo-nicotinic acid methyl ester is a chemical compound with the molecular formula C7H7IN2O2. It is a methyl ester derivative of 6-amino-5-iodo-nicotinic acid and is commonly used as a building block in the synthesis of various organic compounds. This chemical is often utilized in the pharmaceutical and biotechnology industries for the development of new drugs and therapeutic agents. Its properties and structure make it valuable for research and development purposes, particularly in the field of medicinal chemistry. Additionally, 6-amino-5-iodo-nicotinic acid methyl ester may also have potential applications in academic research and industrial processes due to its unique chemical characteristics.

Upstream product

• 36052-24-1 methyl 6-aminonicotinoate 

Downstream Products

• 1202278-09-8 (R)-ethyl 6-(2-(sec-butylamino)thiazol-5-yl)-8-phenylimidazo[1,2-a]pyridine-2-carboxylate 
• 1202276-43-4 (R)-6-(2-(sec-butylamino)thiazol-5-yl)-N-methyl-8-phenylimidazo[1,2-a]pyridine-2-carboxamide 
• 1202278-10-1 (R)-6-(2-(sec-butylamino)thiazol-5-yl)-8-phenyl-imidazo[1,2-a]pyridine-2-carboxylic acid 
• 1312016-90-2 2-{2-cyclopentyl-1(R)-[3-fluoro-4-(1-hydroxy-1-methyl-ethyl)-phenyl]-ethyl}-1H-pyrrolo[2,3-b]pyridin-5-carboxylic acid 
• 1312021-16-1 2-{2-cyclopentyl-1(S)-[3-fluoro-4-(1-hydroxy-1-methyl-ethyl)-phenyl]-ethyl}-1H-pyrrolo[2,3-b]pyridin-5-carboxylic acid 
• 1312016-88-8 2-[2-cyclopentyl-1(R)-(4-methanesulfonyl-phenyl)-ethyl]-1H-pyrrolo[2,3-b]pyridin-5-carboxylic acid 
• 1312016-87-7 2-[2-cyclopentyl-1(R)-(4-methanesulfonyl-phenyl)-ethyl]-1H-pyrrolo[2,3-b]pyridin-5-carboxylic acid methyl ester 
• 1312021-15-0 2-[2-cyclopentyl-1(S)-(4-methanesulfonyl-phenyl)-ethyl]-1H-pyrrolo[2,3-b]pyridin-5-carboxylic acid methyl ester 
• 1312016-85-5 2-[2-cyclopentyl-1(R)-(4-methanesulfonyl-phenyl)-ethyl]-1H-pyrrolo[2,3-b]pyridin-5-carbonitrile 
• 1312021-14-9 2-[2-cyclopentyl-1(S)-(4-methanesulfonyl-phenyl)-ethyl]-1H-pyrrolo[2,3-b]pyridin-5-carbonitrile 
• 1312016-74-2 2-[2-cyclopentyl-1(R)-(4-methanesulfonyl-phenyl)-ethyl]-5-methoxymethyl-1H-pyrrolo[2,3-b]pyridine 
• 1312021-11-6 2-[2-cyclopentyl-1(S)-(4-methanesulfonyl-phenyl)-ethyl]-5-methoxymethyl-1H-pyrrolo[2,3-b]pyridine 
• 1312018-63-5 toluene-4-sulfonic acid 1-(benzenesulfonyl-5-methoxymethyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-2-cyclopentyl-vinyl ester 
• 1312016-00-4 2-[2-cyclopentyl-1(R)-(4-methanesulfonyl-phenyl)-ethyl]-1H-pyrrolo[2,3-b]pyridin-5-carboxylic acid methylamide 

Relevant articles and documents

Synthesis and pharmacological evaluation of 6-aminonicotinic acid analogues as novel GABAA receptor agonists

A series of 6-aminonicotinic acid analogues have been synthesized and pharmacologically characterized at native and selected recombinant GABA A receptors. 6-Aminonicotinic acid (3) as well as 2- and 4-alkylated analogues (9-11, 14-16) display low to mid-micromolar GABAAR binding affinities to native GABAA receptors (Ki 1.1-24 μM). The tetrahydropyridine analogue of 3 (22) shows low-nanomolar affinity (K i 0.044 μM) and equipotency as an agonist to GABA itself as well as the standard GABAA agonist isoguvacine. Cavities surrounding the core of the GABA binding pocket were predicted by molecular interaction field calculations and docking studies in a α1β 2γ2 GABAA receptor homology model, and were confirmed by affinities of substituted analogues of 3. The tight steric requirements observed for the remarkably few GABAAR agonists reported to date is challenged by our findings. New openings for agonist design are proposed which potentially could facilitate the exploration of different pharmacological profiles within the GABAAR area.

SULFOXIMINES AS KINASE INHIBITORS

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

Azaindole derivatives as Factor Xa inhibitors

The present invention relates to compounds of the formula I wherein R0 ; R1 ; R2 ;Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.